Equities

Carna Biosciences Inc

4572:TYO

Carna Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)395.00
  • Today's Change-12.00 / -2.95%
  • Shares traded113.80k
  • 1 Year change-45.96%
  • Beta1.5018
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,8893,3793,818
Total Receivables, Net7881821,244
Total Inventory140119110
Prepaid expenses242286--
Other current assets, total132138146
Total current assets4,1914,1045,318
Property, plant & equipment, net10510052
Goodwill, net------
Intangibles, net1.091.922.74
Long term investments------
Note receivable - long term------
Other long term assets526060
Total assets4,3504,2665,433
LIABILITIES
Accounts payable1.201.962.29
Accrued expenses------
Notes payable/short-term debt000
Current portion long-term debt/capital leases127152239
Other current liabilities, total248282533
Total current liabilities376436775
Total long term debt56148300
Total debt183300540
Deferred income tax------
Minority interest------
Other liabilities, total404042
Total liabilities4726251,117
SHAREHOLDERS EQUITY
Common stock2,0761,3821,057
Additional paid-in capital5,8285,1334,808
Retained earnings (accumulated deficit)(4075)(2905)(1563)
Treasury stock - common(0.22)(0.22)(0.22)
Unrealized gain (loss)(2.72)(2.37)(0.63)
Other equity, total523414
Total equity3,8783,6424,316
Total liabilities & shareholders' equity4,3504,2665,433
Total common shares outstanding171413
Treasury shares - common primary issue0.010.010.01
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.